期刊
FRONTIERS IN MEDICINE
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.693023
关键词
PD1; autologous stem cell transplantation; Hodgkin's lymphoma; beam; case report
资金
- Natural Science Foundation of Chongqing [cstc2019jcyj-msxmX0273, cstc2020jcyjmsxmX1086]
- Science and Technology Innovation Capacity Promotion Project of Army Medical University [2019XLC3014]
- National Key Research Program [2017YFA0105502]
- Special Projects in the Frontier of Military Medicine Natural Science of Xinqiao Hospital [2018 YQYLY002]
The combination of PD-1 monoclonal antibody and autologous stem cell transplantation appears to be a promising regimen for treating refractory Hodgkin's lymphoma, providing a novel approach to treatment in this difficult-to-treat setting.
The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antibody bridging to ASCT and as maintenance after transplantation is a novel approach in HL treatment. In this case, we report that PD-1 monoclonal antibody (mAb) plus ASCT with modified BEAM regimen (carmustine + etoposide + cytarabine + melphalan) containing high-dose cytarabine to treat R/R HL may represent a promising regimen in this difficult-to-treat setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据